T3 Pharmaceuticals grew out of a research project at the University of Basel’sBiozentrum called “Type 3 Technologies – Bacteria as a versatile tool for protein delivery”. It also successfully participated in the BaseLaunch accelerator programm. Founded in 2015, the company uses engineered bacteria to stimulate the immune system by delivering selected human proteins directly into cells of the tumour environment. Preclinical studies have demonstrated a strong impact on tumour progression, and the first clinical trials in humans are expected to start in 2020.
According to a press release, the company has now been named “2018 Science Start-Up of the Year” at this year’s Falling Walls Conference for its ground-breaking work. The conference brings together leading scientists involved in international breakthrough research. It also showcases the most promising research-based startups from around the world.
“We are honoured to receive this prestigious award. We thank the jury for recognizing the medical potential of our immuno-oncology approach,” said T3 Pharma co-founder and CEO Simon Ittig.
T3 Pharma was nominated by the University of Basel.
